TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR/Bupropion SR
Brief Summary: The purpose of this study is to determine the effects of NB relative to placebo on major adverse cardiovascular events (MACE) such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in overweight and obese subjects who are at a higher risk of having these events because they have diabetes and/or other cardiovascular risk factors.


Options:
A: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Sibutramine; Type: EXPERIMENTAL; Interventions: Drug: Sibutramine hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Lead-in sibutramine; Type: EXPERIMENTAL; Interventions: Drug: Sibutramine hydrochloride | Intervention Type: DRUG; Name: Sibutramine hydrochloride; Assigned to Arm(s): Sibutramine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sibutramine hydrochloride; Assigned to Arm(s): Lead-in sibutramine
C: Arm Label: Liraglutide 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: NB32; Type: EXPERIMENTAL; Interventions: Drug: NB32, Behavioral: Weight Management Program | Arm Label: PBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: PBO, Behavioral: Weight Management Program | Intervention Type: DRUG; Name: NB32; Assigned to Arm(s): NB32 | Intervention Type: DRUG; Name: PBO; Assigned to Arm(s): PBO | Intervention Type: BEHAVIORAL; Name: Weight Management Program; Assigned to Arm(s): NB32, PBO

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Wheezing in Black Preterm Infants: Impact of Vitamin D Supplementation Strategy
Brief Summary: The goal of this study is to identify a vitamin D supplementation strategy that best promotes the lung, immune, and overall health of black infants born preterm (28-36 weeks gestational age). This is a high risk population that seems to have unique vitamin D needs, and inappropriate supplementation may promote wheezing or allergy. The results of this study will help form nutritional recommendations for the approximately 100,000 black infants born at 30-36 weeks gestational age in the U.S. every year.


Options:
A: Arm Label: 400 IU Vitamin D3; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol (D3) or ergocalciferol (D2) | Arm Label: 400 IU Vitamin D2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Cholecalciferol (D3) or ergocalciferol (D2) | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol (D3) or ergocalciferol (D2); Assigned to Arm(s): 400 IU Vitamin D2, 400 IU Vitamin D3
B: Arm Label: 10 mcg Vitamin D3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 10 mcg Vitamin D3 | Arm Label: 20 mcg Vitamin D3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 20 mcg Vitamin D3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: 10 mcg Vitamin D3; Assigned to Arm(s): 10 mcg Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: 20 mcg Vitamin D3; Assigned to Arm(s): 20 mcg Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Control 400 IU vitamin D3; Type: ACTIVE_COMPARATOR; Interventions: Drug: 400 IU Vitamin D3 (cholecalciferol) | Arm Label: 2400 IU vitamin D3 (cholecalciferol); Type: EXPERIMENTAL; Interventions: Drug: 2400 IU Vitamin D3 (cholecalciferol) | Arm Label: 6400 IU vitamin D3 (cholecalciferol); Type: EXPERIMENTAL; Interventions: Drug: 6400 IU Vitamin D3 (cholecalciferol) | Intervention Type: DRUG; Name: 400 IU Vitamin D3 (cholecalciferol); Assigned to Arm(s): Control 400 IU vitamin D3 | Intervention Type: DRUG; Name: 2400 IU Vitamin D3 (cholecalciferol); Assigned to Arm(s): 2400 IU vitamin D3 (cholecalciferol) | Intervention Type: DRUG; Name: 6400 IU Vitamin D3 (cholecalciferol); Assigned to Arm(s): 6400 IU vitamin D3 (cholecalciferol)
D: Arm Label: Sustained; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol | Arm Label: Diet-Limited; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol; Assigned to Arm(s): Diet-Limited | Intervention Type: DRUG; Name: Cholecalciferol; Assigned to Arm(s): Sustained

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Wheezing in Black Preterm Infants: Impact of Vitamin D Supplementation Strategy
Brief Summary: The goal of this study is to identify a vitamin D supplementation strategy that best promotes the lung, immune, and overall health of black infants born preterm (28-36 weeks gestational age). This is a high risk population that seems to have unique vitamin D needs, and inappropriate supplementation may promote wheezing or allergy. The results of this study will help form nutritional recommendations for the approximately 100,000 black infants born at 30-36 weeks gestational age in the U.S. every year.


Options:
A: Arm Label: Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Vitamin D supplement; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D at 10 ug/day | Arm Label: Vitamin D supplement at 30 ug/day; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D at 30 ug/day | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D at 30 ug/day; Assigned to Arm(s): Vitamin D supplement at 30 ug/day | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D at 10 ug/day; Assigned to Arm(s): Vitamin D supplement
C: Arm Label: Sustained; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol | Arm Label: Diet-Limited; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol; Assigned to Arm(s): Diet-Limited | Intervention Type: DRUG; Name: Cholecalciferol; Assigned to Arm(s): Sustained
D: Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D2; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Clinical Assessment of an Ultrasound-guided Inserted Peripheral Intravenous Catheter
Brief Summary: Evaluate the safety and efficacy of an an ultrasound-guided inserted peripheral intravenous catheter during a period of seven days.


Options:
A: Arm Label: Midline Catheter; Type: EXPERIMENTAL; Interventions: Device: Midline insertion | Arm Label: Peripheral intravenous cannulation (PIVC); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Midline insertion; Assigned to Arm(s): Midline Catheter
B: Arm Label: Ultrasound Guided Peripheral IV Catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: Ultrasound Guided Peripheral IV Catheter | Arm Label: Midline Catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: Midline Catheter | Intervention Type: DEVICE; Name: Ultrasound Guided Peripheral IV Catheter; Assigned to Arm(s): Ultrasound Guided Peripheral IV Catheter | Intervention Type: DEVICE; Name: Midline Catheter; Assigned to Arm(s): Midline Catheter
C: Arm Label: one intervention arm; Type: EXPERIMENTAL; Interventions: Procedure: peripheral venous puncture | Intervention Type: PROCEDURE; Name: peripheral venous puncture; Assigned to Arm(s): one intervention arm
D: Arm Label: Long Axis approach; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Intravenous access method | Arm Label: Short axis approach; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Intravenous access method | Intervention Type: PROCEDURE; Name: Intravenous access method; Assigned to Arm(s): Long Axis approach, Short axis approach

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Clinical Assessment of an Ultrasound-guided Inserted Peripheral Intravenous Catheter
Brief Summary: Evaluate the safety and efficacy of an an ultrasound-guided inserted peripheral intravenous catheter during a period of seven days.


Options:
A: Arm Label: Easy Access; Type: EXPERIMENTAL; Interventions: Procedure: Ultrasound-guided peripheral intravenous access line placement, Procedure: Landmark Approach to peripheral intravenous access line placement | Arm Label: Difficult Access By Clinician Judgment; Type: EXPERIMENTAL; Interventions: Procedure: Ultrasound-guided peripheral intravenous access line placement, Procedure: Landmark Approach to peripheral intravenous access line placement | Arm Label: Non visible and Non palpable; Type: EXPERIMENTAL; Interventions: Procedure: Ultrasound-guided peripheral intravenous access line placement, Procedure: Landmark Approach to peripheral intravenous access line placement | Intervention Type: PROCEDURE; Name: Ultrasound-guided peripheral intravenous access line placement; Assigned to Arm(s): Difficult Access By Clinician Judgment, Easy Access, Non visible and Non palpable | Intervention Type: PROCEDURE; Name: Landmark Approach to peripheral intravenous access line placement; Assigned to Arm(s): Difficult Access By Clinician Judgment, Easy Access, Non visible and Non palpable
B: Arm Label: Midline; Type: ACTIVE_COMPARATOR; Interventions: Device: Midline | Arm Label: Conventional; Type: ACTIVE_COMPARATOR; Interventions: Device: PVC and/or PICCline | Intervention Type: DEVICE; Name: PVC and/or PICCline; Assigned to Arm(s): Conventional | Intervention Type: DEVICE; Name: Midline; Assigned to Arm(s): Midline
C: Arm Label: Long Axis approach; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Intravenous access method | Arm Label: Short axis approach; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Intravenous access method | Intervention Type: PROCEDURE; Name: Intravenous access method; Assigned to Arm(s): Long Axis approach, Short axis approach
D: Arm Label: one intervention arm; Type: EXPERIMENTAL; Interventions: Procedure: peripheral venous puncture | Intervention Type: PROCEDURE; Name: peripheral venous puncture; Assigned to Arm(s): one intervention arm

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Revascularization With Open Bypass Versus Angioplasty and STenting of the Lower Extremity Trial (ROBUST)
Brief Summary: This is a prospective randomized controlled trial to compare clinical improvement, cost effectiveness and patency rates between new and improved Nitinol stents and open bypass surgery in the superficial femoral artery disease.

Secondary outcomes also include comparing quality of life, re-intervention rate, mortality, morbidity and time to return to work or regular activities.

Patients with superficial femoral artery lesions will be considered. Patients with TASC II A lesions will not be randomized but treated with PTA/stenting as standard of care. Patients with TASC II B and C lesions will be prospectively randomized into either receiving open bypass or stenting.

Patients with TASC D lesions will be treated with open bypass surgery after angiography.

The investigators will collect pre-procedure, peri-procedural and clinical follow-up data on all enrolled the patients.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Exercise Therapy, Drug: Cilostazol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Stent, Drug: Cilostazol | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Device: Stent, Behavioral: Supervised Exercise Therapy | Intervention Type: DEVICE; Name: Stent; Assigned to Arm(s): 2, 3 | Intervention Type: BEHAVIORAL; Name: Supervised Exercise Therapy; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Cilostazol; Assigned to Arm(s): 1, 2
B: Arm Label: Heparin-bonded endoluminal fempop bypass; Type: EXPERIMENTAL; Interventions: Procedure: Heparin-bonded ePTFE endoluminal fem-pop bypass | Arm Label: Surgical femoro-popliteal bypass; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgical femoro-popliteal bypass. | Intervention Type: PROCEDURE; Name: Heparin-bonded ePTFE endoluminal fem-pop bypass; Assigned to Arm(s): Heparin-bonded endoluminal fempop bypass | Intervention Type: PROCEDURE; Name: Surgical femoro-popliteal bypass.; Assigned to Arm(s): Surgical femoro-popliteal bypass
C: Arm Label: REA; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote endarterectomy of the superficial femoral artery | Arm Label: Bypass; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Suprageniculate femoropopliteal bypass | Intervention Type: PROCEDURE; Name: Remote endarterectomy of the superficial femoral artery; Assigned to Arm(s): REA | Intervention Type: PROCEDURE; Name: Suprageniculate femoropopliteal bypass; Assigned to Arm(s): Bypass
D: Arm Label: Open Bypass Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Open Bypass Surgery | Arm Label: Angioplasty and Stenting; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Angioplasty and Stenting | Intervention Type: PROCEDURE; Name: Open Bypass Surgery; Assigned to Arm(s): Open Bypass Surgery | Intervention Type: PROCEDURE; Name: Angioplasty and Stenting; Assigned to Arm(s): Angioplasty and Stenting

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg With Anastrozole (ARIMIDEX) 1 mg as Hormonal Treatment for Postmenopausal Women With Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Been Treated With Any Hormonal Therapy.
Brief Summary: The purpose of the study is to compare how treatment with Fulvestrant (FASLODEX) or Anastrozole (ARIMIDEX) effects disease progression for women with locally advanced or metastatic breast cancer who have not had prior hormonal treatment.


Options:
A: Arm Label: Treatment 1; Type: EXPERIMENTAL; Interventions: Drug: Estradiol, Drug: Progesterone, Drug: Placebo | Arm Label: Treatment 2; Type: EXPERIMENTAL; Interventions: Drug: Estradiol, Drug: Progesterone, Drug: Placebo | Arm Label: Treatment 3; Type: EXPERIMENTAL; Interventions: Drug: Estradiol, Drug: Progesterone, Drug: Placebo | Arm Label: Treatment 4; Type: EXPERIMENTAL; Interventions: Drug: Estradiol, Drug: Progesterone, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Estradiol; Assigned to Arm(s): Treatment 1, Treatment 2, Treatment 3, Treatment 4 | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Treatment 1, Treatment 2, Treatment 3, Treatment 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Treatment 1, Treatment 2, Treatment 3, Treatment 4
B: Intervention Type: DRUG; Name: estradiol, 25 mcg; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Synthetic Conjugated estrogens, B | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Synthetic Conjugated estrogens, B; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: faslodex+placebo; Type: EXPERIMENTAL; Interventions: Drug: faslodex 500mg, Drug: arimidex dummy | Arm Label: arimidex +placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: arimidex 1mg, Drug: faslodex dummy | Intervention Type: DRUG; Name: faslodex 500mg; Assigned to Arm(s): faslodex+placebo | Intervention Type: DRUG; Name: arimidex 1mg; Assigned to Arm(s): arimidex +placebo | Intervention Type: DRUG; Name: faslodex dummy; Assigned to Arm(s): arimidex +placebo | Intervention Type: DRUG; Name: arimidex dummy; Assigned to Arm(s): faslodex+placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Twitter-enabled Mobile Messaging for Smoking Relapse Prevention
Brief Summary: We conducted a two-arm (test vs. control, N=160) randomized controlled trial of small, private, online support groups for quitting smoking with 20 people per group who were seeking to quit smoking. A novel feature was a bot (auto-messenger) that posted a daily cessation-related discussion topic in each group, timed to the group's quit date.


Options:
A: Arm Label: Electronic Referrals; Type: EXPERIMENTAL; Interventions: Other: Electronic Referral | Arm Label: Routine Referral; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Electronic Referral; Assigned to Arm(s): Electronic Referrals
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-delivered continuing professional development | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: No intervention arm | Intervention Type: BEHAVIORAL; Name: Internet-delivered continuing professional development; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: No intervention arm; Assigned to Arm(s): 2
C: Arm Label: Twitter; Type: EXPERIMENTAL; Interventions: Behavioral: smoking cessation aides, Behavioral: Twitter | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: smoking cessation aides | Intervention Type: BEHAVIORAL; Name: smoking cessation aides; Assigned to Arm(s): Control, Twitter | Intervention Type: BEHAVIORAL; Name: Twitter; Assigned to Arm(s): Twitter
D: Arm Label: Telephone counselling; Type: EXPERIMENTAL; Interventions: Device: Standard 15-minute telephone counselling, Device: Proactive telephone counselling | Arm Label: Proactive telephone counselling; Type: EXPERIMENTAL; Interventions: Device: Proactive telephone counselling | Arm Label: web-based smoking cessation programme; Type: EXPERIMENTAL; Interventions: Device: Interactive web-based smoking cessation programme | Arm Label: Self-help material; Type: ACTIVE_COMPARATOR; Interventions: Device: Self-help material | Intervention Type: DEVICE; Name: Standard 15-minute telephone counselling; Assigned to Arm(s): Telephone counselling | Intervention Type: DEVICE; Name: Proactive telephone counselling; Assigned to Arm(s): Proactive telephone counselling, Telephone counselling | Intervention Type: DEVICE; Name: Interactive web-based smoking cessation programme; Assigned to Arm(s): web-based smoking cessation programme | Intervention Type: DEVICE; Name: Self-help material; Assigned to Arm(s): Self-help material

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Twitter-enabled Mobile Messaging for Smoking Relapse Prevention
Brief Summary: We conducted a two-arm (test vs. control, N=160) randomized controlled trial of small, private, online support groups for quitting smoking with 20 people per group who were seeking to quit smoking. A novel feature was a bot (auto-messenger) that posted a daily cessation-related discussion topic in each group, timed to the group's quit date.


Options:
A: Arm Label: Twitter; Type: EXPERIMENTAL; Interventions: Behavioral: smoking cessation aides, Behavioral: Twitter | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: smoking cessation aides | Intervention Type: BEHAVIORAL; Name: smoking cessation aides; Assigned to Arm(s): Control, Twitter | Intervention Type: BEHAVIORAL; Name: Twitter; Assigned to Arm(s): Twitter
B: Arm Label: MiQuit; Type: EXPERIMENTAL; Interventions: Behavioral: MiQuit | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: MiQuit; Assigned to Arm(s): MiQuit
C: Arm Label: Facebook intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Facebook intervention | Arm Label: Referral; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smokefree.gov | Intervention Type: BEHAVIORAL; Name: Facebook intervention; Assigned to Arm(s): Facebook intervention | Intervention Type: BEHAVIORAL; Name: Smokefree.gov; Assigned to Arm(s): Referral
D: Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Standard Care + Text message; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Text Message | Arm Label: Standard Care + Text Message + ABT; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Text Message, Behavioral: Adherence Behavioral Therapy | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Standard Care, Standard Care + Text Message + ABT, Standard Care + Text message | Intervention Type: BEHAVIORAL; Name: Text Message; Assigned to Arm(s): Standard Care + Text Message + ABT, Standard Care + Text message | Intervention Type: BEHAVIORAL; Name: Adherence Behavioral Therapy; Assigned to Arm(s): Standard Care + Text Message + ABT

Answer: A